{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:26Z","timestamp":1753891886137,"version":"3.41.2"},"reference-count":8,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Monoclonal antibodies, such as PD-1 inhibitors, are increasingly used in various cancers. Acute low back pain as infusion-related reaction (IRR) to monoclonal antibodies is poorly described. We report a bicentric series of 10 cases of acute low back pain due to administration of monoclonal antibodies directed against PD-1\/PD-L1 for skin cancer treatment in patients treated at University Hospital Heidelberg and University Medical Center Mainz (Germany). The management of IRR symptoms was immediate interruption of infusion and analgesia leading to quick improvement and complete symptom relief in all patients. Our findings suggest that the risk of developing low back pain as IRR is depending on the concentration of the administered drug. Low back pain as IRR can be managed by early interruption of infusion and by decreasing the infusion rate or concentration in following administrations.<\/jats:p>","DOI":"10.3389\/fonc.2023.1161818","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T21:29:25Z","timestamp":1698182965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute low back pain as infusion-related reaction to monoclonal antibodies"],"prefix":"10.3389","volume":"13","author":[{"given":"Pawel","family":"Majenka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman","family":"Sch\u00f6ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S204909","article-title":"The importance of early identification of infusion-related reactions to monoclonal antibodies","volume":"15","author":"Caceres","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to monoclonal antibodies","volume":"5","author":"Picard","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jcph.818","article-title":"Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors","volume":"57","author":"Agrawal","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2013.09.005","article-title":"Acute epigastric and low back pain during amiodarone infusion; is it the drug or the vehicle to blame","volume":"43","author":"Petrou","year":"2014","journal-title":"Heart Lung"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2004.01.001","article-title":"Acute low back pain during intravenous administration of amiodarone: a report of two cases","volume":"98","author":"Korantzopoulos","year":"2005","journal-title":"Int J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz189","article-title":"Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma","volume":"76","author":"Choi","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14062","article-title":"Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1161818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T21:29:26Z","timestamp":1698182966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1161818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":8,"alternative-id":["10.3389\/fonc.2023.1161818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1161818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"article-number":"1161818"}}